Prucalopride: safety, efficacy and potential applications

被引:54
作者
Quigley, Eamonn M. M. [1 ]
机构
[1] Cork Univ Hosp, Dept Med, Cork, Ireland
关键词
constipation; irritable bowel syndrome; prucalopride; prokinetic; colonic motilty;
D O I
10.1177/1756283X11423706
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic constipation is a very common functional gastrointestinal disorder which can be associated with significant impairments in quality of life for some people with the condition. Its management has, traditionally, been based on dietary and lifestyle changes and the use of a variety of laxative agents. The evidence base for the efficacy of the latter is, in many cases, slim. Not surprisingly, many patients remain dissatisfied with laxatives thus leading to the development of more pharmacological approaches. Among these approaches is the use of prokinetic agents; while prior molecules have been troubled by lack of selectivity and cardiac side effects, the new agent, prucalopride, appears to be highly selective for the serotonin 5-HT4 receptor and is, therefore, a potent stimulator of gut motility. In three large pivotal randomized controlled trials, prucalopride has been effective in relieving the cardinal symptoms of chronic constipation; these effects have been sustained in open-label follow up for as long as 18 months. The safety profile has been encouraging and, especially so, the absence of arrhythmogenic potential. Studies in men, in constipation-predominant irritable bowel syndrome and in other motor disorders are eagerly awaited.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 48 条
[1]  
Boeckxstaens GE, 2002, AM J GASTROENTEROL, V97, P194
[2]   Rectal distention testing in patients with irritable bowel syndrome:: Sensitivity, specificity, and predictive values of pain sensory thresholds [J].
Bouin, M ;
Plourde, V ;
Boivin, M ;
Riberdy, M ;
Lupien, F ;
Laganière, M ;
Verrier, P ;
Poitras, P .
GASTROENTEROLOGY, 2002, 122 (07) :1771-1777
[3]   Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
McKinzie, S .
GUT, 1999, 44 (05) :682-686
[4]   Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
Thomforde, G ;
McKinzie, S ;
Zinsmeister, AR .
GASTROENTEROLOGY, 2001, 120 (02) :354-360
[5]  
Boyce M, 2009, GASTROENTEROLOGY, V136, pT1265
[6]   An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome [J].
Brandt, Lawrence J. ;
Chey, William D. ;
Foxx-Orenstein, Amy E. ;
Quigley, Eamonn M. M. ;
Schiller, Lawrence R. ;
Schoenfeld, Philip S. ;
Spiegel, Brennan M. ;
Talley, Nicholas J. ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 :S1-S36
[7]   Systematic review on the management of chronic constipation in North America [J].
Brandt, LJ ;
Prather, CM ;
Quigley, EMM ;
Schiller, LR ;
Schoenfeld, P ;
Talley, NJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :S5-S22
[8]   Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies [J].
Camilleri, M. ;
Van Outryve, M. J. ;
Beyens, G. ;
Kerstens, R. ;
Robinson, P. ;
Vandeplassche, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (09) :1113-1123
[9]   American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice [J].
Camilleri, M. ;
Bharucha, A. E. ;
Di Lorenzo, C. ;
Hasler, W. L. ;
Prather, C. M. ;
Rao, S. S. ;
Wald, A. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2008, 20 (12) :1269-1282
[10]   Measurement of gastrointestinal motility in the GI laboratory [J].
Camilleri, M ;
Hasler, WL ;
Parkman, HP ;
Quigley, EMM ;
Soffer, E .
GASTROENTEROLOGY, 1998, 115 (03) :747-762